โšกYour ready-to-use recruitment solution: IRB-compliant, SEO-optimized website that automatically routes qualified patient leads to your clinical study (14-day free trial, then $44/mo)

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Sponsored by St. Jude Children's Research Hospital

Quick Self-Assessment

See if you qualify and express your interest

Preparing your pre-screening questions...

Current Status

Recruiting

Auto-verified from ClinicalTrials.gov

Verified Feb 12, 2026

Phase

Clinical Trial

Sponsor

St. Jude Children's Research Hospital

Enrollment Target

128

Start Date

Jan 2025

๐Ÿ“Š
1 of 128 participants interested
1% interest

Express Your Interest Today

Interested in learning more? Complete the form below.

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Advance Medical Science

    Contribute to groundbreaking research

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel (varies by study)

  • Help Others

    Benefit future patients

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3In-person assessment if eligible
  4. 4Begin participation

About This Study

This is a Phase II clinical trial testing the use of two antigen-directed therapies, inotuzumab and blinatumomab, as part of induction therapy for children and young adults with newly diagnosed B-cell precursor acute lymphoblastic leukemia and lymphoma.

Who Can Participate

Inclusion Criteria

Enrollment on INITIALL.
Age 1-18.99 years at the time of enrollment on INITIALL.
B-Acute lymphoblastic leukemia or lymphoblastic lymphoma.
No prior chemotherapy excluding therapy given on or allowed by INITIALL.
NCI high-risk (age 10 years or greater or presenting WBC count โ‰ฅ50,000 cells/microL) or NCI standard-risk and a HR clinical feature as listed below:
CNS3 disease (โ‰ฅ5 WBC/microL CSF with blasts present)
Testicular involvement of leukemia
Steroid pretreatment defined as \>24 hours of therapy in the 14 days prior to enrollment on INITIALL if a preceding WBC to define NCI risk is unavailable
For lymphoblastic lymphoma, Stage 3-4 disease OR Stage 1-2 disease in patient ages โ‰ฅ10 years OR HR clinical feature as defined above.
Adequate liver function defined as:
Total bilirubin โ‰ค 1.5x the upper limit of normal for age and alanine transaminase (ALT) โ‰ค 5x the upper limit of normal for age. Patients with an elevated total bilirubin due

โ“ Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility during the screening process.

Study Details

๐Ÿ“‹

Study Type

INTERVENTIONAL

๐Ÿ‘ฅ

Target Enrollment

128 participants

๐ŸŽ‚

Age Range

1 Year - 18 Years

โšง

Gender

ALL

๐Ÿข

Sponsor

St. Jude Children's Research Hospital

Study Locations

Choose your preferred location or select flexible during enrollment

RECRUITING

Tulsa

Oklahoma

Location available
View Tulsa location page
RECRUITING

Memphis

Tennessee

Location available
View Memphis location page

Frequently Asked Questions

Q:What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Q:Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Q:Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Q:Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

Q:How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Still have questions? Our study coordinators are here to help.

Ready to Make a Difference?

Express your interest in this groundbreaking clinical trial

๐Ÿ”’ Secure ยท ๐Ÿฅ Expert Care

Find More Leukemia Trials by City

Browse all leukemia clinical trials in these cities โ€” not just this study.

Looking for Acute Lymphoblastic Leukemia Treatment in Tulsa?

Join others in Oklahoma exploring innovative treatment options through clinical research

Acute Lymphoblastic Leukemia Treatment Options in Tulsa, Oklahoma

If you're searching for Acute Lymphoblastic Leukemia treatment in Tulsa, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Tulsa, Memphis and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Acute Lymphoblastic Leukemia. All study-related care is provided at no cost to participants.

Local Sites
2 locations in Oklahoma
Now Enrolling
Up to 128 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Acute Lymphoblastic Leukemia?

Potential Benefits

  • โœ“Access to new treatment approaches before public availability
  • โœ“Close monitoring by experienced medical professionals
  • โœ“Study-related care provided at no cost
  • โœ“Contribute to medical research for Acute Lymphoblastic Leukemia

What to Expect

  • โ†’Initial screening to determine eligibility
  • โ†’Regular check-ups and monitoring visits
  • โ†’Possible compensation for time and travel
  • โ†’You can withdraw at any time

Frequently Asked Questions About This Acute Lymphoblastic Leukemia Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT06533748. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.